Related references
Note: Only part of the references are listed.Carbapenem therapy for bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae
Nan-Yao Lee et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2011)
Change in antipseudomonal carbapenem susceptibility in 25 hospitals across 9 years is not associated with the use of ertapenem
Kathryn J. Eagye et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2011)
Pharmacokinetics of Ertapenem following Intravenous and Subcutaneous Infusions in Patients
Denis Frasca et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Absence of Association between Use of Ertapenem and Change in Antipseudomonal Carbapenem Susceptibility Rates in 25 Hospitals
Kathryn J. Eagye et al.
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2010)
Introduction of Ertapenem into a Hospital Formulary: Effect on Antimicrobial Usage and Improved In Vitro Susceptibility of Pseudomonas aeruginosa
Ellie J. C. Goldstein et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
The Impact of Ertapenem Use on the Susceptibility of Pseudomonas aeruginosa to Imipenem: A Hospital Case Study
Ana Lucia L. Lima et al.
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2009)
Ertapenem: No effect on aerobic gram-negative susceptibilities to imipenem
Debra A. Goff et al.
JOURNAL OF INFECTION (2008)
Selectivity of ertapenem for Pseudomonas aeruginosa mutants cross-resistant to other carbapenems
DM Livermore et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2005)
Antimicrobial drug use and methicillin-resistant Staphylococcus aureus, Aberdeen, 1996-2000
DL Monnet et al.
EMERGING INFECTIOUS DISEASES (2004)
Share Paper
